US › Healthcare

ProQR Therapeutics BV (PRQR)

US · Healthcare · Biotechnology

$1.83+7.02%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$2.1M
Revenue YoY
-54.3%
Net profit
$-13.6M
Profit YoY
-35.0%
EPS
$-0.15
EPS estimate
$-0.18
Net margin
-658.3%

EPS came in at -0.15 against a street estimate of -0.18 — a beat of 16.7%.

Key statistics

Market cap
$242.7M
Forward P/E
0.0
P/B
5.68
Book value
$0.41
EPS (TTM)
$-0.50
52-week high
$3.10
52-week low
$1.33
50-day MA
$1.65
200-day MA
$1.84
Beta
0.03

Analyst view

Analysts rate ProQR Therapeutics BV a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $8.25.

Shareholding

Insiders
18.06%
Institutions
42.88%

Largest institutional holders

FundStake
Adage Capital Partners Gp LLC4.43%
Privium Fund Management B.V.3.87%
Aberdeen Group PLC2.35%
Affinity Asset Advisors, LLC1.74%
Sio Capital Management, LLC1.39%
Dafna Capital Management LLC1.11%
Kynam Capital Management, LP1.11%
Ikarian Capital, LLC1.06%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for ProQR Therapeutics BV — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.